Events

New tech brings new hope in our new normal w/ Joanna Shields, WeAreTechWomen

26 JUNE 2020 | VIRTUAL EVENT

Abstract

In recent months the coronavirus pandemic has thrust our global society into a ‘new normal’ which has served as a powerful reminder of the fragile nature of life and health. However, we possess a powerful ally to fight back — AI. In this talk, Joanna Shields will demonstrate how human intelligence partnered with technology promises to accelerate new discoveries, new treatments, and new hope for patients.

Joanna Shields

Joanna Shields (Baroness Shields OBE) is a tech industry veteran with a successful track record building some of the world’s best-known companies. Her career spans over 30 years and has focussed on harnessing the power of technology to drive change that improves connectivity, humanity and society. Prior to joining BenevolentAI, Joanna served as the UK’s first Minister for Internet Safety and Security, Under Secretary of State, Special Advisor on the Digital Economy, and Chair & CEO of TechCityUK.  Before her government service, Joanna held executive roles at Google, Facebook, Bebo/Aol, Decru, RealNetworks, Veon and EFI and served as a non-executive director of the London Stock Exchange Group and TalkTalk Telecom Group.

Joanna founded WePROTECT.org, a multi-stakeholder global alliance working to protect children from online abuse and exploitation. She is a member of the Council on Foreign Relations, the Transatlantic Commission on Election Integrity and the Child Dignity Alliance. In 2014, Joanna was appointed OBE for services to digital industries and voluntary service to young people and made a Life Peer of the House of Lords.

REGISTER >

More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021